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For safe and effective therapy, drugs should be delivered selectively to their target 
tissues or cells at an optimal rate. Drug delivery system technology maximizes the 
therapeutic efficacy and minimizes unfavorable drug actions by controlling their 
distribution profiles. Ligand-receptor binding is a typical example of specific 
recognition mechanisms in the body; therefore, ligand-modified drug carriers have been 
developed for active targeting based on receptor-mediated endocytosis. Among the 
various ligands reported thus far, sugar recognition is a promising approach for active 
targeting because of their high affinity and expression. Glycosylation has been applied 
for both macromolecular and liposomal carriers for cell-selective drug targeting. 
Recently, the combination of ultrasound exposure and glycosylated bubble liposomes 
has been developed. In this review, recent advances of glycosylation-mediated targeted 
drug delivery systems are discussed. 
 





2. Distribution characteristics of macromolecules 
2.1. Overcoming the rapid clearance of macromolecular carriers 
3. Glycosylated macromolecules for cell-selective targeting 
3.1. Galactose modification 
3.2. Mannose modification 
3.3. Mannose-6-phosphate (M6P) modification 
4. Distribution characteristics of liposomes  
4.1. Overcoming the rapid clearance of liposomes 
5. Glycosylated liposomes for cell-selective targeting 
5.1. Galactose modification 
5.1.1. Development of galactosylated liposomes 
5.1.2. Nucleic acids delivery 
5.1.3. Combination of bubble formulation with ultrasound exposure 
5.2. Mannose modification 
5.2.1. Development of mannosylated liposomes 
5.2.2. Nucleic acids delivery 
5.3. Fucose modification 
5.4. M6P modification 





After the administration of drugs to an individual, they are distributed according to 
their physicochemical and/or biological properties. Subsequently, they are eliminated 
from the body. For safe and effective drug therapy, they should be selectively delivered 
to their target tissues or cells at an optimal rate. Drug delivery systems are a technology 
that maximizes drug therapeutic efficacy and minimizes their unfavorable actions by 
controlling distribution profiles. Thus, controlled drug disposition is an important factor 
that determines the therapeutic efficacy of drugs. Drug delivery systems have been used 
clinically, particularly for anticancer drugs and are essential for the practical application 
of recombinant protein and nucleic acid medicine. 
One major approach of targeting is the use of drug carriers that possess an affinity 
towards a population of target cells. To date, many macromolecules and lipid dispersion 
preparations, i.e., liposomes and emulsions, as well as various natural and synthetic 
macromolecules have been developed as drug carriers. Important characteristics of drug 
carriers include: i) biocompatibility, ii) lack of toxicity and immunogenicity, iii) 
biodegradability or minimal accumulation in tissues or organs, iv) adequate functional 
group for chemical modification of ligands and/or drugs, and v) productivity [1,2]. 
Ligand-receptor binding is a typical example of a specific recognition mechanism. 
Therefore, ligand-modified drug carriers have been developed for active cell-selective 
drug delivery by receptor-mediated endocytosis. So far, galactose, mannose, fucose, 
mannose-6-phosphate, sialyl Lewis x, peptides, and proteins (i.e., transferrin, epidermal 
growth factor, and anti-human epidermal growth factor receptor 2 antibodies) have been 
used as ligands [3-10]. Among the various ligands reported, sugar recognition 
mechanisms are a promising approach for active targeting because of their high affinity 
and expression.   
Recently, various nucleic acids have been developed for medication including 
pDNA, antisense DNA, small interfering RNA (siRNA), and microRNA [11-15]. The 
receptor-mediated targeting by glycosylation has been used for therapy with nucleic 
acids. In the case of nucleic acid medicine, not only recognition by receptors but also 
intracellular fate, i.e., endosomal escape, should be considered. To solve this problem, 
multifunctional glycosylated particulates and a combination method of glycosylated 
bubble particles with ultrasound exposure have been developed. This review focuses on 
the recent progress of glycosylation-mediated targeting of low-molecular-weight drugs 





2. Distribution characteristics of macromolecules 
The distribution of macromolecular carriers is determined by their physicochemical 
properties, such as electric charge, molecular size, and hydrophilic/hydrophobic balance. 
Although ligand modifications with a high affinity to target cells are essential for 
macromolecular carriers in active targeting, the physicochemical properties of 
macromolecular carriers have an important function in determining the targeting 
efficacy of ligand-modified macromolecular carriers. The optimal design of 
macromolecules that possess suitable physicochemical properties of distribution 
following their systemic administration should be considered for precise active targeting 
by glycosylated macromolecular carriers.  
  
2.1. Overcoming the rapid clearance of macromolecular carriers 
Prolonged retention of drug-ligand-modified macromolecular carrier conjugates in 
the blood promotes their distribution to target cells. The controlled physicochemical 
properties of macromolecular carriers are an important factor for their prolonged 
retention and are based on the biological characteristics present in tissues and organs. 
These distribution characteristics and pharmacokinetic analysis of macromolecules have 
been summarized in our previous review [1, 2, 18, 19].  
The kidney has an important role in the elimination of drugs from the body. 
Therefore, the reduction of glomerular filtration in the kidney should be considered. 
Macromolecules with a molecular weight of < 50,000 (approximately 6 nm in diameter) 
are suitable for glomerular filtration. In addition, the surface charge of macromolecules 
affects the reabsorption process in the kidney. For example, positively charged dextran 
(70 kDa) has higher glomerular permeation via endocytosis than negatively charged 
dextran although they have a similar molecular weight [20].  
The liver also has an important role in the fate of drugs in the body, and thus the 
reduction of liver uptake should be considered. Our group previously showed that 
positively charged macromolecules (bovine serum albumin (BSA) and dextran) were 
distributed to the liver according to their contact area in the parenchymal and 
non-parenchymal cells via electrostatic interactions [21, 22]. In contrast, negatively 
charged BSA and dextran were distributed to the liver non-parenchymal cells via 
scavenger receptor-mediated endocytosis [23-25].  
It is necessary to consider the general fate of macromolecules from the viewpoint of 
their physicochemical and biological characteristics when rationally designing 




3. Glycosylated macromolecules for cell-selective targeting 
 
Table 1 summarizes an example of cell-selective targeting with macromolecular 
carrier systems based on glycosylation.  Glycosylation-mediated targeting is a 
promising approach for cell-selective 
targeting because it has specificity for 
target cells and productivity for 
standardization. In this case, the 
controlled distribution of non-modified 
macromolecular carriers determined by 
physicochemical properties is important 
for cell-selective targeting. In addition, 
the density of ligands in 
macromolecular carriers might affect 
recognition by the receptor. Fig. 1 
summarizes design of glycosylated 
macromolecular carriers. 
 
3.1. Galactose modification 
Asialoglycoprotein receptors are exclusively expressed on hepatocytes and have a 
high affinity and rapid internalization rate. Therefore, galactosylated macromolecules 
Table 1 An example of glycosylation-mediated targeting of macromolecular carriers 
Target cells Ligand Macromolecular carriers Delivered compounds Ref. 
Liver PC Galactose Poly(L-lysine) ara-AMP 29 
Liver PC Galactose Poly(L-lysine) pDNA 30 
Liver PC Galactose Poly(L-glutamic acid) prostaglandin E1 35 
Liver PC Galactos e Dextran araC 28 
Liver PC Galactose PEI pDNA 38 
Liver PC Galactose Chitosan pDNA 43 
Liver PC Galactose Dendrimer/α-cyclodextrin pDNA 48 
Liver NPC Mannose Poly(L-lysine) Antisense DNA 63 
Liver NPC Mannose Poly(L-lysine) pDNA 64 
Peritoneal macrophages Mannose Chitosan pDNA 71 
Dendritic cells Mannose Chitosan pDNA 72 
Dendritic cells Mannose (Biodegradable) PEI pDNA 70 
HSC M6P HSA doxorubicin 86 
HSC M6P HSA gliotoxin 87 
HSC M6P HSA losartan 89 
HSC M6P HSA Y27632 90-92 
HSC M6P BSA TFO 95,96 
Cancer cells M6P HSA doxorubicin 94 
PC: parenchymal cells 
NPC: non-parenchymal cells 
HSC: hepatic satellite cells 















have been studied for hepatocyte-selective drug targeting. Discontinuous capillaries 
(sinusoidal capillaries) are commonly observed in the liver [26], and contain large 
interendothelial junctions with a mean diameter of 150 nm [26, 27]. Intravenously 
injected galactosylated macromolecules must pass through the sinusoidal capillaries to 
reach the hepatocytes expressing asialoglycoprotein receptors for recognition. To date, 
dextran [28], poly-L-lysine (PLL) [29-33], poly-glutamic acid (PLGA) [34-36], 
polyethlenimine (PEI) [37-42], chitosan[43-47], dendrimer/α-cyclodextrin conjugate 
[48], and their derivatives [49, 50] have been studied for galactosylated macromolecular 
carriers for hepatocyte-selective targeting.   
The design of carrier types based on the physicochemical properties and galactose 
density of the carriers are of significance for targeting efficacy by galactosylated 
macromolecular carriers. Our group previously compared the targeting efficiency 
between positively charged galactosylated PLL and negatively charged galactosylated 
PLGA in mice [51]. After intravenous administration, galactosylated PLGA was 
selectively taken up by liver parenchymal cells and was significantly inhibited by the 
co-administration of excess galactosylated BSA, suggesting the asialoglycoprotein 
receptors mediated uptake of PLGA. Galactosylated PLL showed a higher accumulation 
in the liver compared with unmodified PLL. However, the effect of galactosylation on 
liver parenchymal cells-selective targeting was less pronounced than for galactosylated 
PLGA. These results suggest that the selection of macromolecular carriers is important 
to achieve efficient cell-selective targeting. 
The galactose density of macromolecular carriers might affect targeting efficacy. 
Our group studied the effect of galactose moiety surface density on galactosylated 
proteins such as superoxide dismutase (SOD) and BSA. After intravenous administration 
in mice, galactosylated proteins were recovered in the liver and were shown to be highly 
dependent upon the degree of galactose modification. Thus, targeting efficacy can be 
controlled by the degree of macromolecular carrier galactosylation.  
Hepatocytes are notable targets for gene and nucleic acid therapy, because many 
refractory metabolic diseases are caused by hepatocyte-derived proteins. In addition, 
hepatocytes are considered targets for the production of therapeutic proteins to secrete 
into the blood because the liver possesses a rich blood flow. The asialoglycoprotein 
receptor-mediated targeting of pDNA and/or nucleic acids to hepatocytes using 
galactosylated PLL, galactosylated chitosan, galactosylated PEI, or galactosylated 
dendrimer/α-cyclodextrin conjugate was previously investigated. To achieve high gene 
expression by galactosylated polycations/pDNA complexes, a rationally designed 
delivery system is needed for optimal pharmacokinetics including: i) condensation of 
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pDNA for the penetration of fenestrae, ii) pharmacokinetic processes of pDNA to 
hepatocytes by asialoglycoprotein receptor recognition, and iii) release of pDNA from 
endosomes/lysosomes into cytoplasm after internalization. Of these, the release of 
pDNA from endosomes/lysosomes into the cytoplasm after internalization is a major 
obstacle for efficient gene expression in hepatocytes. Therefore, manipulation of this 
process by functional peptides or the use of PEI with pH buffering functions in 
lysosomes [53] by galactosylated macromolecules might allow high transfection rates in 
vivo [40, 49, 54-56].   
 
3.2. Mannose modification 
Macrophages have an important role as effector cells in inflammation and antigen 
presentation. Mannose receptors are expressed on Kupffer cells, alveolar, peritoneal, and 
splenic macrophages, dendritic cells, and a subset of vascular endothelial cells [57-61]. 
Therefore, mannosylated macromolecules have been studied for mannose 
receptor-expressing cell-selective targeting. Similar to galactosylated macromolecular 
carriers described above, dextran [28], PLL [62-64], PLGA [65], PEI [66-70], chitosan 
[71-73], and dendrimer/α-cyclodextrin conjugate [74, 75] have been studied for 
mannosylated macromolecular carriers to selectively target mannose receptor expressing 
cells. The design of carrier types based on the physicochemical properties and mannose 
density of the carriers is of significance for targeting efficacy by mannosylated 
macromolecular carriers.   
Our group developed a mannosylated macromolecular carrier system for 
cell-selective targeting based on dextran, which has high solubility, an abundance of 
hydroxyl groups for chemical modification, low immunogenicity, and is used in the 
clinic as a plasma expander [2]. Our group studied carboxymethyl dextran to minimize 
the interaction with endogenous components and then coupled them with mannose 
moieties as a ligand [28]. After intravenous injection into mice, mannosylated 
carboxymethyl dextran was rapidly eliminated from the plasma and accumulated in liver 
non-parenchymal cells including Kupffer cells and liver endothelial cells that expressed 
mannose receptors. When we compared the targeting efficiency between positively 
charged mannosylated PLL and negatively charged mannosylated PLGA in mice [51], 
the liver non-parenchymal cell selectivity of mannosylated PLL was lower than for 
mannosylated PLGA. These observations correspond with results observed for 
galactosylated macromolecular carriers. Thus, the selection of macromolecular carriers 




Similar to galactosylated macromolecular carriers, the mannose density of 
macromolecular carriers can affect the targeting efficacy. We previously reported the 
effect of the surface density of mannose moieties in mannosylated proteins such as SOD, 
BSA, and IgG [76]. After intravenous administration in mice, mannosylated proteins 
were recovered in the liver and were highly dependent on the degree of mannose 
modification. These results suggest that targeting efficacy can be controlled by the 
degree of mannosylation of macromolecular carriers. 
Mannose-expressing cells are notable targets for gene and nucleic acid therapy for 
refractory diseases such as chronic inflammation, cancer, and virus infection, amongst 
others. Mannose receptor-mediated targeting of pDNA and/or nucleic acids to 
macrophages was previously reported using mannosylated PLL, and mannosylated 
chitosan. When considering mannosylation, the condensation of pDNA is not critical 
because it is not required to pass through fenestrae to reach the target cells unlike 
galactosylated macromolecular carriers. However, the release of pDNA from 
endosomes/lysosomes into the cytoplasm after internalization is a major obstacle for 
efficient gene expression in mannose receptor-expressing cells. To solve this problem, 
mannosylated PEI, or mannosylated dendrimer/α-cyclodextrin conjugate that can 
accelerated the cytoplasmic release of pDNA have been investigated.   
 
3.3. Mannose-6-phosphate (M6P) modification 
Two M6P receptors, cation-dependent M6P receptors and cation-independent 
M6P/insulin-like growth factor (M6P/IGF-II), belong to the family of p-type lectins and 
are involved in the transport of cellular proteins from the cellular surface or trans-golgi 
network to lysosomes [77-79]. M6P/IGF-II receptors are highly expressed on activated 
hepatic stellate cells (HSCs) [80-82]. Liver fibrosis is the excessive accumulation of 
extracellular matrix proteins including collagen. Excessive collagen is considered 
responsible for activated HSCs, which constitute 5–8% of liver cells [83].   
M6P modification of macromolecular carriers has been studied for cell-selective 
targeting to HSCs or cancer cells that highly express M6P/IGF-II receptors. M6P 
modified human serum albumin (HSA) was accumulated in the liver by an 
M6P-modification-dependent mechanism [84]. After intravenous administration, 
M6P28-HSA (M6P:HSA=28:1) preferentially accumulated in HSCs of fibrotic rats and 
liver endothelial cells in normal rats. In contrast, M6P28-HSA predominantly 
accumulated in liver endothelial cells in normal rats, suggesting a degree of the fibrosis 
is required for the M6P modification targeting system. These results demonstrate the 
importance of targeting efficacy to HSCs determined by the degree of M6P expression 
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of macromolecular carriers in fibrotic rats. This observation corresponds with 
galactosylated and mannosylated macromolecular carriers as previously described. In 
addition, the uptake of M6P-HSA in slices of human liver was reported [85].   
HSC-selective targeting by macromolecular carriers has been studied using 
various drugs conjugated to M6P-HSA. Greupink et al. developed a doxorubicin 
(DOX)-conjugated M6P-HSA (M6P-HSA-DOX) for HSC-selective targeting of bile 
duct-ligated rats [86]. They showed that M6P-HSA-DOX was distributed in the liver 
and immunohistochemical double staining revealed accumulation in HSCs. In addition, 
M6P-HSA-DOX reduced HSC proliferation by 82% in vitro. These results indicate that 
inhibition of activated HSC proliferation by cytostatic drugs can prevent the fibrotic 
process. Similarly, Hagens et al. developed glitoxin (GTX), an apoptosis-inducing agent, 
conjugated with M6P-HSA (M6P-HSA-GTX), which attenuated liver fibrosis in bile 
duct-ligated rats [87]. Although GTX induced adverse effects on hepatocytes, 
M6P-HSA-GTX did not show such effects. To date, various drugs including tyrosine 
kinase inhibitor, angiotensin type 1 receptor blockers, Rho kinase inhibitor, and 
conjugated M6P-HSA have been developed to inhibit liver fibrosis [88-93]. Prakashi et 
al. reported tumor-selective targeting by M6P-HSA-DOX through M6P/IGF-II receptors 
in tumor-bearing mice [94]. 
Regarding oligonucleotide delivery, Ye et al. developed M6P-BSA conjugated 
with oligonucleotides via a disulfide bond [95]. A triplex-forming oligonucleotide (TFO) 
was used to inhibit transcription via interactions with genomic DNA. After intravenous 
injection, M6P20-BSA-[33P]TFO was rapidly eliminated from the blood and a significant 
increase in uptake by the liver was observed. Study of intrahepatic distribution revealed 
that M6P20-BSA-[33P]TFO was preferentially taken up by HSCs compared with 
hepatocytes, Kupffer cells and/or endothelial cells. In addition, pre-injection of excess 
M6P20-BSA significantly decreased the liver uptake in normal and fibrotic rats, 
suggesting M6P/IGF-II receptors mediated the uptake of M6P20-BSA-TFO [96]. Zhu et 
al. developed siRNA-PEG-M6P conjugates for hepatic stellate cell-selective targeting 
[97]. Although there have been few reports regarding nucleic acid delivery using M6P 
modified macromolecules, the release from endosomes/lysosomes into the cytoplasm 
after internalization is a common obstacle for efficient gene expression in HSCs. 
 
4. Distribution characteristics of liposomes 
Liposomes have been used in the clinic as drug delivery carriers [98-100]. 
Therefore, targeted drug delivery by surface modification of liposome ligands is a 
promising approach for their wide application and delivery of drugs. In general, the 
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distribution of liposomes is greatly determined by their surface charge, particle size, 
lipid composition, and dose used. A major factor that determines their rapid elimination 
is their uptake by the reticuloendothelial (mononuclear phagocyte) system, 
predominantly the liver and spleen. Phagocytosis of liposomes is accelerated by 
association with complement and immunoglobulins in the blood. The optimal design of 
liposomal dosage is one that possesses suitable physicochemical properties, especially 
avoiding uptake by the reticuloendothelial system upon systemic administration and this 
should be considered for precise active targeting using glycosylated liposomes. 
 
4.1. Overcoming the rapid clearance of liposomes 
After intravenous administration, liposomes are taken up by the reticuloendothelial 
system in the liver and spleen [101]. Therefore, the reduction and/or blockage of the 
reticuloendothelial system uptake are promising approaches to enhance the blood 
concentration of liposomes. 
The lipid composition of liposomes might affect the clearance of liposomes 
depending on the contents and type of lipids present. Regarding the effect of cholesterol 
incorporation in liposomes, cholesterol-free liposomes and cholesterol-poor (20 mol%) 
liposomes were cleared more readily from blood circulation than cholesterol-rich (46.6 
mol%) liposomes [102]. The predominant factor of clearance from the blood circulation 
is uptake by the reticuloendothelial tissues. Semple et al. analyzed the in vivo 
association of blood proteins with liposomes composed of saturated 
phosphatidylcholines and cholesterol [103]. When liposomes composed of 
dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), 
distearylphosphatidylcholine (DSPC), and diarachidoylphosphatidylcholine (DAPC) 
were administered intravenously, liposomes containing DMPC and DOPC, that are 
liquid crystalline prior to injection, showed relatively long circulation times. In contrast, 
liposomes composed of DPPC, DSPC, and DAPC that are in a gel state at 39ºC, were 
rapidly cleared from blood circulation and were associated with large quantities of 
associated blood proteins. The incorporation of cholesterol into DSPC liposomes 
resulted in their deceased protein binding and enhanced circulation time in blood.  
The surface charge of liposomes might also affect the clearance of liposomes. 
Juliano et al. reported that neutral liposomes containing phosphatidyl choline and 
cholesterol at a 1:1 ratio and positively charged liposomes containing phosphatidyl 
choline, stearyl amine, and cholesterol at an 18:2:10 ratio were cleared less rapidly than 
negatively charged liposomes containing phosphatidyl choline, phosphatidyl serine, and 
cholesterol at a 1:1:1 ratio [104]. Allen et al. reported that the incorporation of greater 
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than 2 mol% phosphatidyl serine into liposomes caused their rapid elimination from 
blood circulation. Daeman et al. reported a different intrahepatic distribution of 
phosphatidyl glycerol and phosphatidyl serine liposomes [105]. Phosphatidyl 
serine-containing liposomes were found mainly in the liver (75%), while phosphatidyl 
glycerol-containing liposomes were found in the liver (40%) and spleen (40%) equally. 
Regarding intrahepatic distribution, phosphatidyl serine-containing liposomes were 
distributed between Kupffer cells and hepatocytes equally, while phosphatidyl 
glycerol-containing liposomes were only taken up by Kupffer cells. Gabizon and 
Papahadjopoulos reported that increasing the molar ratio of negatively charged 
phosphatidyl inositol from 9% to 23% did not change the distribution, but an increase 
from 23% to 41% accelerated the clearance of liposomes [106]. It was reported that 
cationic liposomes/plasmid DNA (lipoplex) can be selectively transfected to lungs 
following intravenous administration [107-109]. We previously showed that cationic 
liposomes containing 1,2-di-O-octadecenyl-3-trimethylammonium propane or 
N-[1-(2,3-dioleoyloxy)propyl]-N, N, N-trimethylammonium methyl sulfate and 
cholesterol at a 1:1 ratio that were used for gene transfection were mainly distributed in 
the lung [110]. This is consistent with the transfection characteristics of lipoplex. 
Therefore, the selection of lipid composition is important when designing targeted drug 
delivery systems using glycosylated liposomes.   
Surface modification of liposomes by ganglioside GM1 [111] and poly(ethylene 
glycol) (PEG) [112, 113] could achieve long blood circulation by avoiding 
reticuloendothelial uptake from the blood. To date, many reports have described the use 
of PEGylated liposomes for long blood circulation. Woodle et al. reported the effect of 
various molecular weights (120, 750, 1,900, and 5,000) of PEG conjugated with 
distearoylphosphatidylethanolamine (DSPE)-modified liposomes on prolonged blood 
circulation [114]. They reported that longer forms of PEG with molecular weights of 
1,900 and 5,000 kDa used to PEGylate liposomes with a size of about 100 nm 
prolonged their circulation in the blood. Maruyama et al. also reported a similar effect 
using large unilamellar liposomes with a size about 200 nm [115]. DOX-encapsulated 
liposomes showed enhanced tumor distribution through enhanced permeability and 
retention effects [116] and reduced adverse effects of DOX, especially cardiac toxicity 
[98, 117]. A DOX-encapsulated PEGylated liposome formulation (Doxil®) was 
approved by the US Food and Drug Administration in 1995. Recently, the development 
of Doxil® was reviewed by Barenholz et al. [98].  
Although PEG modification of liposomes is a promising approach, the immune 
response against PEGylated liposomes should be considered for their therapeutic use. 
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Dams et al. reported that repeated injections of PEGylated liposomes significantly 
altered the pharmacokinetics of subsequently injected PEGylated liposomes [118]. A 
second dose of injected PEGylated liposomes was rapidly cleared from the blood. They 
studied the factors affecting the accelerated blood clearance of subsequently injected 
PEGylated liposomes [118]. Macrophage deletion experiments using 
clodronate-containing liposomes [120] provided evidence that Kupffer cells and spleen 
macrophages were involved in the reduced blood circulation. This effect did not depend 
on liposomal size but rather on lipid dose. In addition, they found that 
DOX-encapsulated PEGylated liposomes did not induce the enhanced clearance of a 
second injected “empty” PEGylated liposome. Ishida et al. also systemically 
investigated the accelerated clearance of subsequent PEGylated liposome administration 
[121-123] and demonstrated that PEGylated liposomes induced PEG-specific IgM that 
were responsible for the rapid elimination of second injected PEGylated liposomes [124, 
125]. Furthermore, the induction of anti-PEG-specific IgM that recognized 
DOX-encapsulated PEGylated liposomes was significantly lower than that for “empty” 
PEGylated liposomes [126]. This observation partly explains the observation by 
Laveman et al. described above [119]. Such information about the immunological 
responses induced by PEGylated liposomes is important for the design of glycosylated 
liposomes. 
 
5. Glycosylated liposomes for cell-selective targeting 
Glycosylated liposomes have been studied for cell-selective delivery of drugs. It is 
important to consider the glycosylation methods used. Thus far, glycosylation of 
liposomes is achieved using glycoproteins or synthetic glycolipids attached to the 
liposomal surface. Compared with glycoproteins, it is easy to control synthetic 
glycolipids for targeting. Because glycosylated liposomes interact with endogenous 
components in blood, the hydrophobicity of synthetic glycolipids is important for stable 
incorporation in vivo. In addition, an adequate spacer length in synthetic glycolipids is 
required to display the ligands for recognition by receptors. Ligand modified PEGylated 
lipids have been used to display ligands on the surface of PEGylated liposomes because 
of a steric hindrance effect caused by PEG. However, PEG might be immunogenic. 
Thus, the design of glycosylated liposomes should be considered in a comprehensive 
way according to their application to disease.  Fig. 2 summarizes the design of 
glycosylated liposomes by glycosylated lipids. 
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 Recently, there has been increasing attention paid to nucleic acid drugs and their 
application for refractory diseases. Various glycosylated liposomes have been developed 
for cell-selective delivery. However, both receptor recognition and release of nucleic 
acids from endosomes/lysosomes into the cytoplasm after internalization should be 
considered. 
Table 2 summarizes an example of cell-selective targeting with liposomal carrier 
systems based on glycosylation. In this section, the use of glycosylated liposomes for 




5.1. Galactose modification 
Similar to galactosylated macromolecular carriers, galactosylated liposomes have 
been studied as hepatocyte-selective targeting agents via asialoglycoprotein 
receptor-mediated uptake. To date, glycoproteins or synthetic glycolipids have been 
used to prepare galactosylated liposomes for targeted delivery.  
 
5.1.1. Galactosylated liposomes 
For efficient recognition by hepatocytes via asialoglycoprotein receptors, a rational 
design of galactosylated liposomes is required. Asialofetuin is a glycoprotein that 
possesses several tri-antennary galactose-terminated sugar chains, and is taken up by the 
Table 2 An example of glycosylation-mediated targeting of liposomal carriers 
Target cells Ligand Administration route Delivered compounds Ref. 
Liver PC Asialofetuin Intravenous injection cholesterol 128 
Liver PC Asialofetuin Intravenous injection vitamin E, DiI 130 
Liver NPC (Tris) galactose Intravenous injection inulin 131 
Liver PC (Tris) galactose Intravenous injection cholesteroryl oleate 132 
Liver PC (Mono, bi, tris) 
galactose 
Intravenous injection inulin 135 
Liver PC Galactose Intravenous injection CHE 138, 139 
Liver PC Galactose Intravenous injection probucol 140 
Liver PC Galactose (PEG) Intravenous injection doxorubicin 143 
Liver PC Galactose Intravenous injection stavudin 136 
Liver PC Galactose Intraportal injection pDNA 156,160 
Liver PC Galactose Intravenous injection pDNA 168 
Liver PC Galactose Intravenous injection siRNA 171, 172, 173 
Liver NPC Mannose, Fucose Intravenous injection CHE 179 
Liver NPC Mannose Intravenous injection pDNA 192, 194 
Liver NPC Mannose Intravenous injection NFκB decoy 195 
Liver NPC Mannose (bubble) Intravenous injection siRNA 218 
Peritoneal macrophages (Oligo) mannose Intraperitoneal injection soluble leishmanial antigen  204 
Peritoneal macrophages (Oligo) mannose Intraperitoneal injection ovalbumin 205 
DC Mannose Intravenous injection mRNA 188 
DC Mannose (bubble) Intravenous injection pDNA 211 
Alveolar macrophages Mannose Intratracheal injection dexametasone palmitate 202 
Alveolar macrophages Mannose Intratracheal injection NFκB decoy 202 
TAM Mannose (bubble) Intratumoral injection NFκB decoy 219 
Liver NPC Fucose Intravenous injection NFκB decoy 225 
Pancreatic cancer cells Fucose Intravenous injection cisplatin 226 
HSC M6P Intravenous injection HSA-doxorubicin conjugate 227 
HSC M6P Intravenous injection DLPL 229 
 
PC: parenchymal cells 
NPC: non-parenchymal cells 
DC: Dendritic cells  
TAM: tumor associated macrophages 





liver after intravenous administration in rats [127]. Tsuchiya et al. developed 
asialofetuin-modified liposomes for hepatocyte-selective targeting of drugs [128]. 
Asialofetuin was conjugated with palmitic acid, a hydrophobic anchor that fixes 
asialofetuin on to the liposomal surface. After intravenous administration, 
asialofetuin-modified liposomes were rapidly eliminated from the blood, and most were 
recovered from the liver [129]. Intrahepatic distribution studies revealed that 
asialofetuin-modified liposomes were selectively found in liver parenchymal cells [130] 
and Wu et al. reported that asialofetuin-modified liposomes distributed in the liver in 
combination with intravenously injected vitamin E improved the protective effect 
against CCl4-induced acute liver injury in mice [130].   
Synthetic glycolipids have been designed and studied for cell-selective targeting. 
Spanjer et al. reported that tri-antennary galactose-terminated cholesterol (tri-gal-chol) 
modified liposomes were efficiently distributed to the liver [131]. However, an 
intrahepatic distribution study showed that tri-gal-chol-modified liposomes were taken 
up by liver non-parenchymal cells (including Kupffer cells) via galactose/fucose 
recognizing receptors and not by liver parenchymal cells via the asialoglycoprotein 
receptors in rats. However, a rapid exchange of tri-gal-chol to endogenous components 
in the blood occurred because of the relatively high hydrophilicity of tri-gal-chol [132]. 
Sliedregt et al. synthesized a hydrophobic tri-gal-chol by adding one or more fatty acid 
chains to the glycolipid to increase their stable incorporation in galactosylated 
liposomes [132]. They found that 5% (mol) hydrophobic tri-gal-chol-modified 
galactosylated liposomes were taken up by asialoglycoprotein receptors on liver 
hepatocytes. In contrast, 50% (mol) hydrophobic tri-gal-chol-modified galactosylated 
liposomes were taken up by the galactose/fucose recognizing receptors on Kupffer cells 
in the liver. Sasaki and Murahashi et al. synthesized various synthetic galactosyl lipids 
to prepare galactosylated liposomes [133, 134] and found that galactose density on 
galactosylated liposomes was a critical factor for hepatocyte-selective targeting rather 
than the branching structure of the galactosylated lipid [135]. Recently, Garg et al. 
observed that uptake of galactosylated liposomes with a low galactosyl lipid content by 
parenchymal cells was significantly higher than for non-parenchymal cells [136]. This 
corresponded with a report by Sliedregt et al. [132]. These observations demonstrate the 
importance of the galactose density of galactosylated liposomes as well as the design of 
synthetic galactosylated lipids for hepatocyte-selective delivery. 
For hepatocyte-selective targeting, our group synthesized 
cholesten-5-yloxy-N-(4-((1-imino-2-D-thiogalactosylethyl)amino)butyl)formamide 
(Gal-C4-Chol), a galactosylated cholesterol derivative, to prepare galactosylated 
16 
 
liposomes [137]. Introduction of many hydrophilic galactose moieties to a hydrophobic 
anchor might result in their removal by interaction with endogenous components in the 
blood. Therefore, one galactose moiety was conjugated to cholesterol via a spacer. After 
intravenous administration in mice, 5% (mol) Gal-C4-Chol-modified galactosylated 
liposomes were efficiently distributed to liver parenchymal cells [138]. The high uptake 
in liver parenchymal cells was observed the 3.5, 5.0, and 7.5% (mol) for 
Gal-C4-Chol-modified galactosylated liposomes [139]. To determine the effect of lipid 
composition in targeting, we prepared 5% (mol) Gal-C4-Chol-modified galactosylated 
liposomes involving different egg phosphatidylcholine or DSPC and cholesterol 
contents [140, 141]. Liver parenchymal cells selectivity was significantly affected by 
the lipid composition of galactosylated liposomes, suggesting that the lipid composition 
of galactosylated liposomes should be considered for cell-selective targeting. 
 To achieve a targeted and sustained drug delivery by galactosylated liposomes, 
we prepared polysorbate (Tween) 20 or 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-polyethylene glycol 
(PEG(x)-DSPE) where x represents a mean molecular weight of PEG (2,000 or 350 
kDa), which was added to galactosylated liposomes [142]. Incorporation of Tween 20 
and PEG-DSPE reduced blood elimination and hepatic uptake. Furthermore, the 
incorporation of PEG350-DSPE into galactosylated liposomes could control delivery to 
hepatocytes without losing its targeting capabilities. Recently, Wang et al. developed a 
novel cleavable PEG lipid, PEG2,000-cholesteryl hemisuccinate (PEG2,000-CHEMS), that 
can be metabolized by esterases in plasma and tissues, for targeted and sustained 
targeting into hepatocytes [143]. The incorporation of PEG2,000-CHEMS into 
galactosylated liposomes directed the delivery of encapsulated DOX into hepatocytes 
without losing its targeting capability. DOX-encapsulated PEGylated and galactosylated 
liposomes exhibited the highest inhibitory effect in hepatocarcinoma 22-bearing mice. 
Therefore, a controlled and targeted method is an effective strategy to exert a high 
pharmacological effect of drugs used for therapy.  
 Regarding low-molecular-weight drug delivery, studies have reported the 
delivery of anti-cancer drugs to hepatocellular carcinomas (HCC). Xiao et al. 
synthesized a tetravalent galactosylated diethylenetriaminepenta-acetic acid-distearoyl 
phosphatidylethanolamine (4Gal-DTPA-DSPE) to prepare doxorubicin encapsulated 
galactosylated liposomes [144]. Either 5 or 10% (mol) of 4Gal-DTPA-DSPE was added 
to lipids to prepare galactosylated liposomes. Galactosylated liposomes had a prolonged 
blood retention and high liver accumulation after intravenous administration. Study of 
intrahepatic distribution demonstrated galactosylated liposomes selectively accumulated 
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in hepatocytes. As an example of applications for drug delivery, vitamin E [130], 
probucol [140], prostaglandin E1 [145], DOX [146], retinoic acids [147], ara-C [148], 
N4-Octadecyl-1-β-D-arabinofuranosylcytosine [148], and stabudine [136, 149] have 
been used for hepatocyte-selective targeting. Because asialoglycoprotein receptors are 
expressed on normal hepatocytes, tumor selectivity is required for a rational cancer 
therapy. Our group developed a novel drug delivery system using enzymatic activity 
expressed specifically in tumors. It was reported that matrix metalloprotease-2 
(MMP-2) plays a critical role in tumor progression, angiogenesis, and metastasis, and 
are overexpressed in HCC [150-153]. Using the enzymatic activity of MMP-2 could 
provide HCC-selective properties to galactosylated liposomes. Thus, our group 
developed a novel functional lipid, cleaved by the protease activity of MMP-2. The 
amino group of dioleoylphosphatidylethanolamine (DOPE) was conjugated [148] with 
PEGylated MMP-2 substrate peptide (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln), and 
MMP-2-cleavable PEG-peptide-DOPE (PEG-PD) was synthesized. PEG-PD 
incorporated galactosylated liposomes were taken up by human hematoma HepG2 cells 
in a dose-dependent manner and was dependent upon MMP-2 expression. Hatakeyama 
et al. also reported that a PEG-PD-modified multifunctional envelope-type nano device 
for tumor-selective delivery of pDNA and siRNA used the enzymatic degradation of the 
peptide by MMP-2 [153-155].  
 
5.1.2. Nucleic acid delivery 
Our group investigated the hepatocyte-selective delivery of nucleic acids using 
galactosylated cationic liposomes based on their physicochemical properties. 
Pharmacokinetic analysis of pDNA complexed with galactosylated PLL demonstrated 
that physicochemical properties such as charge and size of complexes should be 
optimized for efficient hepatocyte-selective targeting [32]. Therefore, we investigated 
the hepatocyte-selective delivery of pDNA using galactosylated cationic liposomes 
based on their physicochemical properties [156]. When pDNA was complexed with 
galactosylated cationic liposomes (galactosylated lipoplexes) via electrostatic 
interactions, a 5% glucose solution enabled the preparation of about 140-nm-sized 
galactosylated lipoplexes at a relatively high concentration for in vivo use. The cationic 
charge ratio (−:+) of galactosylated lipoplexes was from 1.0:2.3 to 1.0:3.1 and showed 
high gene expression in the liver. Furthermore, hepatocyte-selective gene expression 
was observed when lipoplexes were prepared at a charge ratio (−:+) of 1.0:2.3. In 
addition, galactosylation of the lipoplexes increased the tissue binding and 
internalization rate via asialoglycoprotein receptor-mediated endocytosis on hepatocytes 
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[157]. Letrou-Bonneval et al. reported that galactosylated multi-modular lipoplexes 
prepared at a charge ratio (−:+) of 1.0:2.0 showed asialoglycoprotein receptor-mediated 
transfection in primary cultured rat hepatocytes [158]. Penetration across the fenestrated 
sinusoidal endothelium by galactosylated lipoplexes might be limited. In addition, 
lipoplexes easily aggregate in higher salt concentrations [159]. Therefore, a reduction in 
size or improved stability of galactosylated lipoplexes in higher salt conditions would 
be a promising approach to enhance the transfection activity in hepatocytes. To solve 
this problem, we developed stabilized galactosylated lipoplexes by adding moderate 
amounts of sodium chloride during lipoplex formation based on our surface charge 
regulation (SCR) theory [160]. Galactosylated SCR lipoplexes had a mean diameter of 
120 nm and had high stability in a high ionic solution (150 mM NaCl). The hepatic 
transfection activity of galactosylated SCR lipoplexes was about 10- to 20-fold higher 
than that of galactosylated lipoplexes. The pre-administration of excess galactosylated 
BSA inhibited hepatic gene expression in galactosylated SCR lipoplexes, suggesting the 
involvement of asialoglycoprotein receptor-mediated uptake on hepatocytes.  Thus, 
controlling the physicochemical properties of galactosylated lipoplexes is important for 
the efficient hepatocyte-selective targeting of DNA. 
Cationic-charged galactosylated lipoplexes interact with non-target cells or 
erythrocytes [161] via electrostatic interaction, therefore the use of PEGylated lipids 
would be a promising strategy to reduce such non-specific interactions. Perouzel et al. 
synthesized various glycosylated cholesterol derivatives to prepare glycosylated cationic 
liposomes, adenovirus core peptides, and pDNA ternary complexes [162]. Then, 
PEG2,000-DSPE were incorporated into glycosylated ternary complexes by pre- or 
post-modification methods. Although a stabilizing effect was observed by the 
incorporation of PEG2,000-DSPE (5-10% (mol)) in high salt conditions, transfection into 
HeLa cells was abolished using the same preparation conditions. Therefore, galactose 
might be required to conjugate the terminal of PEG2,000 displayed on the liposomal 
surface for both efficient recognition by asialoglycoprotein receptors and the prevention 
of complex aggregation in higher salt conditions. As an alternate strategy, the use of 
degradable PEGylated lipids by either acid [163] or enzyme [148, 153] would be 
promising approach. Frisch et al. synthesized a novel galactosylated lipid. To display 
galactose moieties, a tri-antennary galactose moiety was attached to the distal end of the 
PEGylated lipids. The positive charge of the galactosylated-PEGylated lipoplexe was 
shielded by the PEG effect to some extent. Chloroquine inhibits endosomal maturation 
and can enhance the transfection activity of lipoplexes [164]. In the presence of 
chloroquine, targeted gene transfection was observed in human hepatoma HepG2 cells, 
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suggesting asialoglycoprotein receptor-mediated uptake. This result is in accord with 
those reported by our group using galactosylated lipoplexes [165]. These results also 
suggest that the pharmacokinetic process of endosomal escape is a rate-limiting process 
for efficient gene expression.   
Considering these findings, both biodistribution and intracellular distribution 
should be controlled for efficient gene expression in hepatocytes. Therefore, a 
multifunctional carrier system by galactosylation should be developed. The use of a pH 
buffering effect could be an effective strategy to enhance transfection efficiency by 
promoting the release of drugs from the endosome to cytoplasm. Our group focused on 
histidine (His), an amino group with a pKa of 6.0. We synthesized a novel pH-sensitive 
histidine-modified galactosylated cholesterol derivative (Gal-His-C4-Chol), for efficient 
transfection to hepatocytes [166]. Galactosylated lipoplexes containing 
Gal-His-C4-Chol showed much greater transfection activity in HepG2 cells than 
conventional galactosylated lipoplexes and was dependent upon an asialoglycoprotein 
receptor-mediated mechanism. Recently, our group also demonstrated that 
lysine-histidine dendron-modified chitosan could improve the transfection efficiency of 
chitosan based on pH buffering capacity in HEK293 cells [167]. Recently, Hu et al. 
developed multifunctional galactosylated and PEGylated lipoplexes for the efficient 
nuclear delivery of pDNA in mice. In this multifunctional system, galactose, PEG, 
calcium phosphate, and monocyclic octa-arginine were introduced to control both 
biodistribution and intracellular distribution processes [168]. A high gene expression 
was observed in mouse hepatocytes. Therefore, both biodistribution and intracellular 
distribution should be considered as efficient strategies to obtain high gene expression 
in hepatocytes.  
RNA interference (RNAi) can be induced by double-stranded siRNA, 
consisting of 21–25 nucleotides, which is incorporated into the RNAi-induced silencing 
complex and is a guide for cleavage of complementary target messenger RNA (mRNA) 
in the cytoplasm [169, 170]. An effective delivery system is essential for the application 
of siRNA as clinical treatment. Our previous study demonstrated that a siRNA 
(Ubc-13)/galactosylated cationic liposomes complex was efficiently delivered to 
hepatocytes [171]. Sonoke et al. also reported the hepatocyte-selective delivery of 
siRNA (firefly luciferase) using siRNA/galactosylated cationic liposomes complexes 
[172]. Regarding the use of these complexes for clinical use, Jiang et al. prevented liver 
ischemia reperfusion or concanavalin A-induced hepatitis via the hepatocyte-selective 
delivery of siRNA using siRNA/galactosylated cationic liposomes complexes [173, 




5.2. Mannose modification 
Similar to mannosylated macromolecular carriers, mannosylated liposomes 
have been studied for macrophage- and/or dendritic cell-selective targeting via mannose 
receptor-mediated uptake in various tissues. To date, mannosylated lipids have been 
used to prepare mannosylated liposomes for targeted delivery.    
 
5.2.1. Development of mannosylated liposomes 
Mannose-containing phospholipids from the cell wall of mycobacteria [175] 
and synthetic mannosylated lipids [176-191] have been used to prepare mannosylated 
liposomes for drug delivery or imaging of macrophages and/or dendritic cells. 
Mannosylated liposomes have been used for the treatment of diseases such as infections, 
inflammation, and cancer, etc.. 
For macrophage- and/or dendritic cell-selective targeting, our group 
synthesized cholesten-5-yloxy-N-(4-((1-imino-2-D-thiomannosylethyl)amino)butyl) 
formamide (Man-C4-Chol), a galactosylated cholesterol derivative, to prepare 
mannosylated liposomes [179]. To deliver drugs into macrophage- and/or dendritic cell 
in various tissues, we investigated various administration routes including intravenous 
[179, 192-197], intraperitoneal [198-201], and intratracheal [202, 203] administration. 
In addition, vaccination of peptides by subcutaneous [178] and intraperitoneal [204, 
205] routes have been studied. Mannosylated liposomes were efficiently taken up by 
macrophages and/or dendritic cells in various tissues according to each administration 
route.   
To obtain efficient recognition of complexes via mannose receptors expressed 
by macrophages, the rational design of mannosylated liposomes is required. Engel et al. 
synthesized alkylmannoside derivatives that possessed a hydrophobic anchor and 
hydrophilic head group containing a PEG spacer with increasing length between the 
hydrophilic head group and hydrophobic anchor moieties [182]. The effect of PEG as a 
spacer on macrophage uptake was investigated using mannosylated liposomes with 
alkylmannoside derivatives. Cellular uptake was increased by increasing PEG numbers 
of alkylmannoside derivatives. Thus, the spacer length of synthetic mannosylated lipids 
in mannosylated liposomes is important for recognition by mannose receptors on 
macrophages. Mannose density of mannosylated liposomes is also an important factor 
in the recognition of mannose receptors. Espuelas et al. synthesized multi-branched 
mannosylated lipids [186]. The dimannosylated ligands were recognized as efficiently 
as tetramannosylated lipids by mannose receptors expressed on immature human 
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dendritic cells. Man-C4-Chol contents in mannosylated liposomes enhanced the uptake 
of mannosylated liposomes from 2.5 to 7.5% (mol) by mannose receptor-mediated 
endocytosis in cultured rat alveolar macrophages [202]. This finding is in line with our 
previous report using mannosylated emulsion in mouse peritoneal macrophages [206]. 
Chono et al. showed that the uptake of bare liposomes by rat alveolar macrophages was 
dependent on particle size (100, 200, 400, 1,000, and 2,000 nm) and that mannosylation 
of liposomes with 4-aminophenyl-α-D-mannopyranoside enhanced uptake [185]. These 
results suggest the structure of mannosylated lipids, mannose density, and size of 
mannosylated liposomes should be optimized for efficient recognition by mannose 
receptors on macrophages and/or dendritic cells.  
Examples of drug delivery or imaging applications by encapsulation of 
muramyl dipeptide [193], stavudine [184], dexamethasone palmitate [202], cytidine 5’ 
diphosphocholine [187], amphotericin B [189], 64Cu [191], and indocyanine green [206] 
have been reported. Similarly, encapsulation of various peptides to induce cytotoxic T 
lymphocytes for vaccination have been investigated [178, 204, 205]. 
 
5.2.2. Nucleic acid delivery 
 pDNA, NF-κB decoy, mRNA, and siRNA have been used for delivery to 
macrophages and/or dendritic cells. We investigated macrophage- and/or dendritic 
cell-selective delivery of nucleic acids using mannosylated cationic liposomes based on 
their physicochemical properties. Because it is not necessary to pass through fenestrae 
in the liver to reach Kupffer cells and liver endothelial cells, we prepared 200-nm-sized 
pDNA/mannosylated lipoplexes [192]. After intravenous administration in mice, the 
highest gene expression was observed in liver non-parenchymal cells including Kupffer 
cells and liver endothelial cells. A cationic charge ratio (−:+) of mannosylated 
lipoplexes from 1.0:2.3 to 1.0:3.1 demonstrated high gene expression in the liver [208]. 
When complexes were formed with higher charge ratios, transfection efficiency in the 
lung was highest, indicating non-specific interactions. These findings correspond with 
our previous reports of galactosylated lipoplexes in vivo and in situ [156, 157]. 
Consideration of the administration route is also important for pDNA delivery. After 
intravenous administration, many mannosylated lipoplexes were rapidly taken up by the 
liver [194]. Therefore, the intraperitoneal administration route was selected to avoid 
rapid uptake by Kupffer cells and achieve sustained gene expression in macrophages 
and dendritic cells, but not Kupffer cells [198]. Following intraperitoneal administration 
of mannosylated lipoplexes into mice, high gene expression was observed in 
macrophages and dendritic cells from peritoneally exuded cells and the spleen. This 
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supports a report by Ikehara et al. using ovalbumin-encapsulated oligomannose-coated 
liposomes via intraperitoneal administration [205]. Recently, Li et al. reported that 
mannosylated liposome/protamine/pDNA complexes exhibited a high transfection 
activity in bone marrow-derived dendritic cells [209] supporting the view that lipoplex 
mannosylation is an efficient strategy to obtain high transfection activity in 
macrophages and/or dendritic cells. 
To control endosomal escape, we synthesized a histidine-modified 
mannosylated cholesterol derivative (Man-His-C4-Chol), for efficient transfection to 
macrophages [210]. Mannosylated lipoplexes containing Man-His-C4-Chol functioned 
similarly to galactosylated lipoplexes containing Gal-His-C4-Chol, and showed a higher 
transfection activity than conventional mannosylated lipoplexes, via a mannose 
receptor-mediated mechanism both in vivo and in vitro. These results are consistent with 
those recently reported by Perche et al. [188]. Therefore, both biodistribution and 
intracellular distribution could be useful strategies to obtain high gene expression in 
macrophages and/or dendritic cells.  
The use of nucleic acids, DNA or mRNA vaccination for cytotoxic T 
lymphocyte induction [188, 199, 200, 211], CpG DND for cancer immunotherapy [196, 
201], and NF-κB decoy delivery for anti-inflammatory therapy [H195, 203] has been 
reported.  
 
5.2.3. Combination of bubble formulation with ultrasound exposure 
Fig. 3 summarizes the combination method of glycosylated liposomes with 
physical stimuli for targeted drug delivery. Microbubbles can be destroyed by 
ultrasound exposure to generate microstreams or microjets. Consequently, transient 
holes are generated in cellular membranes. Therefore, the combined use of ultrasound 
exposure and microbubble formulation used as ultrasound contrast agents can enhance 
the transfection efficacy of naked pDNA by facilitating pDNA entry into the cells [212]. 
Suzuki et al. prepared ultrasound imaging gas-encapsulated liposomes (bubble 
liposomes) for naked pDNA mediated transfection in mice [213]. The bubble liposomes 
had a small size (about 446 nm) compared with conventional microbubble formulation 
[212]. We developed mannosylated bubble liposome/pDNA complexes (mannosylated 
bubble lipoplexes) for efficient cell-selective gene transfection with ultrasound exposure 
[214-217]. This system could be used for delivery of oligonucleotides such as siRNA or 
NF-κB decoy delivery into liver NPC [218] or tumor-associated macrophages [219]. 
Because cationic-charged bubble lipoplexes interact with erythrocytes, we developed 
ultrasound-responsive anionic-charged bubble lipopolyplexes as a platform of 
23 
 
glycosylation for safe transfection [220]. Therefore, optimization of physicochemical 
properties of mannosylated bubble formulations might be used for safe and efficient 
gene transfection into macrophages and/or dendritic cells. Another glycosylated bubble 
formulation, sialyl LewisX-modified microbubbles were previously developed for 
molecular imaging applications [221, 222]. 
 
 
5.3. Fucose modification 
Fucosylated liposomes have been studied as carriers for Kupffer cell or 
pancreatic cancer cell-selective delivery. Fucose rectin is found exclusively in hepatic 
Kupffer cells [223]. We synthesized 
cholesten-5-yloxy-N-(4-((1-imino-2-D-thiofucosylethyl)amino)butyl)formamide, a 
fucosylated cholesterol derivative, to prepare the fucosylated liposomes [179]. 
Intravenously injected fucosylated liposomes were rapidly taken up by the liver and 
were recovered from liver NPC. An in vitro uptake study using primary cultured rat 
sinusoidal endothelial cells and Kupffer cells demonstrated that fucosylated BSA was 
taken up by both sinusoidal cells and Kupffer cells [224]. The uptake of fucosylated 
BSA was significantly inhibited in the presence of excess mannosylated BSA and 
fucosylated BSA. In addition, fucosylated BSA was more Kupffer cell selective than 
mannosylated BSA. Thus, fucosylated liposomes might be more selective as Kupffer 
cell-targeting carriers.   
Based on these findings, we investigated the use of fucosylated liposomes for 
NF-κB decoy delivery into Kupffer cells for the treatment of acute hepatitis [225]. 
NF-κB decoy was mainly recovered from liver NPC following the intravenous 
administration of fucosylated cationic liposomes/NF-κB decoy complexes (fucosylated 
complexes). In an acute hepatitis model, proinflammatory cytokines, alanine 
transaminase, and aspartate transaminase serum levels in LPS-infected mice were 
significantly attenuated by treatment with fucosylated complexes. 
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Recently, Yoshida et al. reported the pancreatic cancer cell-selective delivery of 
cisplatin using fucosylated liposomes by simultaneous injection of excess D-mannose (5 
mg) to inhibit the hepatic uptake in tumor-bearing mice [226]. Under these experimental 
conditions, fucosylated liposomes selectively accumulated in pancreatic cancer cells and 
efficiently inhibited tumor growth as well as prolonging survival of tumor-bearing mice.   
 
5.4. M6P modification 
M6P/IGF II receptors are expressed on hepatic stellate cells [80-82] and 
M6P-modified liposomes have been studied as carriers for hepatic stellate cell-selective 
delivery. Kamps et al. conjugated M6P-HSA to the surface of liposomes for hepatic 
stellate cell-selective targeting [227-229]. In bile duct-ligated rats, M6P-HSA-modified 
liposomes selectively accumulated in hepatic stellate cells. Greupink et al. reported that 
M6P-HSA-DOX-conjugated modified liposomes inhibited hepatic stellate cell 
proliferation in bile duct-ligated rats. Similarly, Adrian et al. reported the use of 
M6P-HSA-modified liposomes or hemagglutinating virus of Japan liposomes for 
hepatic stellate cell-selective targeting [230, 231]. Therefore, M6P-modified liposomes 




6. Future Perspectives 
Although this review focused on glycosylated macromolecules and liposomes, 
glycosylated polymeric micelles would be a promising approach for targeted drug and 
gene delivery [232-235].  Kataoka et al. have reviewed the recent progress of the 
functional polymeric micelles for drug and gene delivery [236, 237].  
For targeted drug delivery by glycosylation, both the glycosylation method and 
physicochemical properties should be optimized to achieve efficient cell-selective 
targeting by macromolecular and liposomal carriers. For nucleic acid delivery, the 
control of intracellular delivery is also required because of nucleic acid degradation by 
lysosomal enzymes. Therefore, introduction of functional groups that facilitate 
endosomal/lysosomal escape might be an effective strategy to improve transfection 
activity.  Hossain and Akaike et al. reported that carbonate apatite/siRNA complex can 
facilitate the intracellular delivery of siRNA [238]; therefore the development of such a 
new carrier for glycosylation is important. To exploit the shielding effects of PEG, the 
use of biodegradable PEG cleaved by enzymes or low pH might provide a new targeting 
system. Moreover, the combined use of physical stimuli such as ultrasound exposure 
could enable enhanced targeting efficacy by glycosylated liposomes [239]. Because the 
use of ultrasound exposure is a promising approach, further optimization of the 
physicochemical properties and/or development of glycosylated lipids for glycosylated 
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